A 7-year-old boy is brought to the child psychiatry clinic by his mother with complaints of inattention and poor academic performance. The teacher reports that he frequently interrupts classmates, fidgets constantly in class, and struggles to follow instructions. At home, he loses toys, forgets to complete homework, and is unable to sit through meals. His mother reports he was a hyperactive infant and has always been "on the go." Physical examination is unremarkable. His IQ is average. Which of the following is the most appropriate first-line pharmacological intervention for this child?

Explanation

## Diagnosis and Management of ADHD ### Clinical Presentation This child meets DSM-5 criteria for Attention-Deficit/Hyperactivity Disorder (ADHD), Combined Type, with symptoms present across multiple settings (school and home), onset before age 12, and functional impairment in academic and social domains. **Key Point:** The presence of inattention (loses items, forgetfulness, difficulty following instructions) combined with hyperactivity-impulsivity (fidgeting, interrupting, restlessness) across multiple settings for >6 months is diagnostic of ADHD Combined Type. ### First-Line Pharmacotherapy | Drug Class | Agent | Mechanism | Onset | Duration | First-Line? | |---|---|---|---|---|---| | Stimulants | Methylphenidate | Blocks DA/NE reuptake | 30–60 min | 3–4 hrs (IR) / 8–12 hrs (ER) | **Yes** | | Stimulants | Amphetamine | Blocks DA/NE reuptake | 30–60 min | 4–6 hrs (IR) / 10–13 hrs (ER) | **Yes** | | Non-stimulants | Atomoxetine | Selective NE reuptake inhibitor | 2–4 weeks | 24 hrs | Second-line | | Antipsychotics | Risperidone | D~2~ antagonist | Variable | Variable | Only for comorbid aggression/conduct | | Antidepressants | Fluoxetine | SSRI | 2–4 weeks | Variable | Only for comorbid depression/anxiety | | Anticonvulsants | Valproate | GABA enhancement | Variable | Variable | Not indicated in ADHD | **High-Yield:** Methylphenidate and amphetamine salts are first-line pharmacological agents for ADHD in children. They are equally effective; choice depends on individual response and tolerability. ### Mechanism of Action Stimulants increase dopamine and norepinephrine in the prefrontal cortex and striatum, enhancing executive function, attention, and impulse control. **Clinical Pearl:** Response to stimulants is rapid (within 1–2 weeks) and dose-dependent. Titration should be gradual (starting 5 mg methylphenidate daily) with weekly monitoring for efficacy and adverse effects. ### Dosing in Children - **Methylphenidate:** Start 5 mg once or twice daily; titrate by 5 mg increments weekly; usual range 10–60 mg/day in divided doses (IR) or 18–72 mg once daily (ER). - **Amphetamine salts:** Start 5 mg once daily; titrate by 5 mg increments; usual range 5–40 mg/day. **Warning:** Stimulants are contraindicated in uncontrolled hypertension, cardiac arrhythmias, or active substance use disorder. Baseline cardiovascular assessment (BP, HR, ECG if indicated) is recommended. ### Non-Pharmacological Adjuncts - Behavioral parent training and classroom accommodations are essential and should be initiated concurrently with medication. - Cognitive-behavioral therapy (CBT) for older children and adolescents. **Key Point:** Medication alone is insufficient; multimodal treatment (medication + behavioral intervention + educational support) yields the best outcomes.